(Q36031532)

11 August 2017

1 reference

title

Pharmacoeconomic impact of non-compliance with statins (English)

1 reference

11 August 2017

Andrew M Peterson

1

1 reference

PubMed ID

15693725

11 August 2017

William F McGhan

series ordinal

2

1 reference

11 August 2017

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

23

1 reference

11 August 2017

1

1 reference

11 August 2017

13-25

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-200523010-00002

11 August 2017

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Cost-effectiveness analysis for statin therapies in the primary prevention of coronary heart disease in Italy

1 reference

12 December 2020

Prescription and adherence to statins of patients with coronary artery disease and hypercholesterolemia

1 reference

12 December 2020

Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens

1 reference

12 December 2020

Cost-effectiveness of statins

1 reference

12 December 2020

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease

1 reference

12 December 2020

Postcard and telephone reminders for unclaimed prescriptions: a comparative evaluation using survival analysis

1 reference

12 December 2020

Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings?

1 reference

12 December 2020

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

12 December 2020

Accounting for noncompliance in pharmacoeconomic evaluations

1 reference

12 December 2020

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction

1 reference

12 December 2020

Primary non-compliance with prescribed medication in primary care

1 reference

12 December 2020

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

1 reference

12 December 2020

Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

12 December 2020

Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

1 reference

12 December 2020

Weekly versus daily dosing of atorvastatin.

1 reference

12 December 2020

Persistence of use of lipid-lowering medications: a cross-national study

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction

1 reference

12 December 2020

Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.

1 reference

12 December 2020

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

12 December 2020

Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.

1 reference

12 December 2020

Determinants of the cost-effectiveness of statins

1 reference

12 December 2020

10.2165/00019053-200523010-00002

Identifiers

DOI

1 reference

PubMed ID

15693725

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15693725